Related scientific articles (all)

Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?

Authors : Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, Preusser M, Saba L
Year : 2018
Journal : Crit Rev Oncol Hematol
Volume : 126
Pages : 135-144

Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors : Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH
Year : 2018
Journal : Ann Oncol
Volume : 29(2)
Pages : 405-417

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Authors : Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, Tkint de Roodenbeke D, de Azambuja E, Ignatiadis M, Demeestere I
Year : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 237-243

Tackling the challenges of brain metastases in solid tumors.

Authors : Kotecki N, Awada A
Year : 2018
Journal : Curr Opin Oncol
Volume : 30
Pages : 330-331

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Authors : Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos P, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Year : 2018
Journal : J Clin Oncol
Volume : 36
Pages : 3007-3014

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

Authors : Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart-Gebhart M
Year : 2018
Journal : Pharmacogenomics J
Volume : 18
Pages : 480-486

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Authors : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pages : 23

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Authors : Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber Rd, Goldhirsch A, Regan MM, + collaborators (among others :, Piccart-Gebhart M
Year : 2018
Journal : N Engl J Med
Volume : 379
Pages : 122-137

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Authors : Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Marechal R, Gomez Galdon M, Heimann P, Paesmans M, Flamen P, Hendlisz A
Year : 2018
Journal : Oncotarget
Volume : 9
Pages : 17756-17769

Quality management for systemic treatment of breast cancer

Authors : Verhoeven D, Duhoux FP, de Azambuja E, Wildiers H, Vuylsteke P, Barbeaux A, Van Damme N, Van Eycken E
Year : 2018
Journal : Belgian J Medical Oncology
Volume : 11(1)
Pages : 15-21

Baseline hepcidin measurement in the differential diagnosis of anaemia for elderly patients and its correlation with the increment of transferrin saturation following an oral iron absorption test.

Authors : Wolff F, De Breucker S, Pepersack T, Compté N, Mélot C, Gulbis B, Cotton F
Year : 2018
Journal : Clin Chem Lab Med
Volume : 52(2)
Pages : 250-258

CDK4/6 blockade in breast cancer: current experience and future perspectives.

Authors : Zardavas D, Pondé N, Tryfonidis K
Year : 2017
Journal : Expert Opin Investig Drugs
Volume : 26
Pages : 1357-1372

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors : Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M
Year : 2017
Journal : Lancet Oncol
Volume : 18(7)
Pages : 904-916

Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Authors : Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, Van Velthoven R
Year : 2017
Journal : BJU Int
Volume : 120(2)
Pages : 197-203

Paratesticular liposarcoma, an unsual presentation of testicular mass.

Authors : El Hachem N, Jungels C, Gil T, Sideris S
Year : 2017
Journal : Int J Cancer Res Dev
Volume : 2(1)
Pages : 1-3

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Authors : Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S
Year : 2017
Journal : Nat Commun
Volume : 8
Pages : 606

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2901-2905

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Year : 2017
Journal : N Engl J Med
Volume : 377(2)
Pages : 122-131

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Authors : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Year : 2017
Journal : Ann Oncol
Volume : 28(1)
Pages : 16-33

Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.

Authors : Assi T, Kourie HR, El Rassy E, Moussa T, Kattan J
Year : 2017
Journal : Anticancer Drugs
Volume : 28
Pages : 931-933